Status:
UNKNOWN
Dosage of Tacrolimus Metabolites in Blood and Bile for Prediction of Its Side Effects in Liver Transplant Recipients
Lead Sponsor:
Rennes University Hospital
Conditions:
Blood Concentration of Tacrolimus Metabolites
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate if concentration of tacrolimus metabolites is increased in patients presenting tacrolimus (TAC) side effects.
Detailed Description
The study will evaluate whether the blood concentration of TAC metabolites (13-O-desmethyl-tacrolimus, 15-O-desmethyl-tacrolimus and 31-O-desmethyl-tacrolimus), measured between Day1 and Day5 of its i...
Eligibility Criteria
Inclusion
- Adult patients (\> 18 years) of both sexes,
- Candidates for liver transplantation or retransplantation, whatever the etiology and severity of the underlying disease,
- Not having expressed their opposition to participation in the study
Exclusion
- Associated transplantation of another organ
- Contraindications to TAC administration
- Delayed introduction of TAC (beyond the 5th postoperative day) whatever the cause.
Key Trial Info
Start Date :
May 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 8 2024
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT05277792
Start Date
May 8 2022
End Date
June 8 2024
Last Update
July 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Rennes
Rennes, France, 35033